Shots:
- The company has decided to discontinue the P-IIb Imbokodo, POC efficacy study that evaluates HIV vaccine regimen in ~2600 young women across five countries in sub-Saharan Africa
- The results showed that the HIV vaccine regimen did not provide sufficient protection against HIV infection. The vaccine was found to be safe with no serious AEs & no vaccine-related safety signals were observed
- Following the discussion with DSMB, J&J’s HIV vaccine program continues to advance in ongoing P-III Mosaico HIV study in MSM and transgender individuals across the America and EU where different strains of HIV are circulating
Click here to read full press release/ article | Ref: J&J | Image: Law.com
The post Johnson & Johnson Discontinues the P-IIb Imbokodo Trial of HIV Vaccine Regimen for HIV Infection first appeared on PharmaShots.
